Journal of Clinical Endocrinology & Metabolism, Vol 80, 1816-1821, Copyright © 1995 by Endocrine Society

ARTICLES

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism

W Oelkers, JM Foidart, N Dombrovicz, A Welter and R Heithecker
Division of Endocrinology, Klinikum Benjamin Franklin (Steglitz), Freie Universitat, Berlin, Germany.

Combined hormonal oral contraceptives (OCs) may lead to a mild rise in blood pressure and body weight. In rare instances, large increments in blood pressure are measured. We investigated the effect of a combination of ethinyl estradiol (EE) plus a progestogen with antimineralocorticoid, i.e. natriuretic, properties [Drospirenone (DRSP)] on body weight, blood pressure, the renin-aldosterone system, atrial natriuretic factor, plasma lipids, and glucose tolerance. It is anticipated that this will lead to the development of an OC that does not raise body weight or blood pressure. Four groups of 20 women each received 30 micrograms EE plus 3 mg DRSP (group A), 20 micrograms EE plus 3 mg DRSP (group B), 15 micrograms EE plus 3 mg DRSP (group C), and, as a control OC, 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, Schering; group D) for 6 months. During the OC-free control cycles before and after treatment and throughout treatment, the target parameters were measured. Between the pretreatment cycle and the sixth treatment cycle, mean body weight fell by 0.8 to 1.7 kg in groups A, B, and C (P < 0.05 vs. D), whereas it rose by 0.7 kg in group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in groups A, B, and C (significant for A and C vs. D) and increased by 1-2 mm Hg in group D. Renin substrate rose equally in all groups (P < 0.05), whereas PRA and plasma aldosterone rose significantly only in the DRSP groups, presumably due to sodium loss. In the DRSP groups, high density lipoprotein cholesterol rose (P < 0.05), in contrast to group D. Low density lipoprotein cholesterol fell slightly (P > 0.05), whereas triglyceride levels showed a stronger increase in the DRSP groups (P < 0.05) than in group D. All groups attained good cycle control; group A had the best. Side-effects were minimal. To our knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure. It may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.

This article has been cited by other articles:

				A. H. Karara, V. Hanes, A. Alonso, P. Ni, N. Poola, R. Silang, H. Blode, and R. A. Preston Pharmacokinetics and Pharmacodynamics of Drospirenone-Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women J. Clin. Pharmacol., October 1, 2007; 47(10): 1292 - 1302. [Abstract] [Full Text] [PDF]

				C. Meyer, B. P. McGrath, and H. J. Teede Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome Diabetes Care, March 1, 2007; 30(3): 471 - 478. [Abstract] [Full Text] [PDF]

				I. Milsom, I. Lete, A. Bjertnaes, K. Rokstad, I. Lindh, C.J. Gruber, M.H. Birkhauser, E. Aubeny, T. Knudsen, and C. Bastianelli Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 {micro}g ethinyl estradiol and 3 mg drospirenone Hum. Reprod., September 1, 2006; 21(9): 2304 - 2311. [Abstract] [Full Text] [PDF]

				R. Schurmann, H. Blode, N. Benda, M. Cronin, and A. Kufner Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J. Clin. Pharmacol., August 1, 2006; 46(8): 867 - 875. [Abstract] [Full Text] [PDF]

				W. B. White, V. Hanes, V. Chauhan, and B. Pitt Effects of a New Hormone Therapy, Drospirenone and 17-{beta}-Estradiol, in Postmenopausal Women With Hypertension Hypertension, August 1, 2006; 48(2): 246 - 253. [Abstract] [Full Text] [PDF]

				D. A. Sica Drospirenone: An Antihypertensive in Waiting Hypertension, August 1, 2006; 48(2): 205 - 206. [Full Text] [PDF]

				R. Sitruk-Ware New progestagens for contraceptive use Hum. Reprod. Update, March 1, 2006; 12(2): 169 - 178. [Abstract] [Full Text] [PDF]

				W. B. White, B. Pitt, R. A. Preston, and V. Hanes Antihypertensive Effects of Drospirenone With 17{beta}-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension Circulation, September 27, 2005; 112(13): 1979 - 1984. [Abstract] [Full Text] [PDF]

				M. Guido, D. Romualdi, M. Giuliani, R. Suriano, L. Selvaggi, R. Apa, and A. Lanzone Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2817 - 2823. [Abstract] [Full Text] [PDF]

				M. F. Gallo, D. A. Grimes, K. F. Schulz, and F. M. Helmerhorst Combination Estrogen-Progestin Contraceptives and Body Weight: Systematic Review of Randomized Controlled Trials Obstet. Gynecol., February 1, 2004; 103(2): 359 - 373. [Abstract] [Full Text] [PDF]

				E. C. Raney and J. Methot Recent Advances in Hormonal and Barrier Contraception Journal of Pharmacy Practice, June 1, 2003; 16(3): 209 - 217. [Abstract] [PDF]

				Is {blacktriangledown}Yasmin a "truly different" pill? DTB, August 1, 2002; 40(8): 57 - 59. [Abstract] [Full Text] [PDF]

				J. Ribstein, J.-M. Halimi, G. du Cailar, and A. Mimran Renal Characteristics and Effect of Angiotensin Suppression in Oral Contraceptive Users Hypertension, January 1, 1999; 33(1): 90 - 95. [Abstract] [Full Text] [PDF]